Pleurectomy/decortication
Hyperthermic intrathoracic extracorporeal chemotherapy for secondary malignant pleural disease
Journal of Surgical Oncology 2023 September [Link] Daniel L Miller, Christopher S Parks, Brittany Ange, Ioana R Bonta, Patricia T Rich Abstract Objectives: Pleural metastasis has extremely poor prognosis. Resection of pleural implants with infusion of intrathoracic hyperthermic chemotherapy may offer a survival advantage in selected patients. We evaluated the safety and efficacy of hyperthermic…
Read MoreGene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
Genes, Chromosomes, & Cancer 2023 July 8 [Link] Maymun Jama, Min Zhang, Charlotte Poile, Apostolos Nakas, Annabel Sharkey, Joanna Dzialo, Alan Dawson, Kudazyi Kutywayo, Dean A Fennell, Edward J Hollox Abstract Malignant pleural mesothelioma (MPM), a rare cancer a long latency period (up to 40 years) between asbestos exposure and disease presentation. The mechanisms coupling…
Read MoreEpigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos
Scientific Reports 2023 April 20 [Link] Giulia Di Mauro, Francesca Frontini, Elena Torreggiani, Maria Rosa Iaquinta, Andrea Caselli, Chiara Mazziotta, Valentina Esposito, Elisa Mazzoni, Roberta Libener, Federica Grosso, Antonio Maconi, Fernanda Martini, Ilaria Bononi, Mauro Tognon Abstract The epigenetic role of microRNAs is established at both physiological and pathological levels. Dysregulated miRNAs and their targets…
Read MoreHigh mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma
Histopathology 2023 April 11 [Link] Gerard J Chu, Anthony Linton, Steven Kao, Sonja Klebe, Stephen Adelstein, Dannel Yeo, John E J Rasko , Wendy A Cooper Abstract Aims: Mesothelin (MSLN) is a cancer-associated antigen that is overexpressed in malignancies such as mesothelioma, pancreatic and ovarian cancer. It is also a target for novel personalised therapies,…
Read MoreDisparities in Survival Due to Social Determinants of Health and Access to Treatment in US Patients With Operable Malignant Pleural Mesothelioma
JAMA Network Open 2023 March 1 [Link] Ahmed Alnajar, Samuel A Kareff, Syed S Razi, J Sunil Rao, Gilberto De Lima Lopes, Dao M Nguyen, Nestor Villamizar, Estelamari Rodriguez Abstract Importance: Outcomes of localized malignant pleural mesothelioma (MPM) remain poor despite multimodality therapy. It is unclear what role disparities have in the overall survival (OS)…
Read MorePleurectomy and decortication are associated with better survival for bicavitary cytoreductive surgery for mesothelioma compared with extrapleural pneumonectomy
Journal of Thoracic and Cardiovascular Surgery 2022 December 14 [Link] R Taylor Ripley, Hudson M Holmes, Richard S Whitlock 2, Shawn S Groth, Cristian G Medina, Eugene A Choi, Bryan M Burt, Paul H Sugarbaker Abstract Objectives: Mesothelioma is a nearly uniformly fatal tumor. Multimodality therapy including cytoreductive surgery and chemotherapy is associated with long-term…
Read MoreImportance of Histopathological Grading for Treatment Selection in Malignant Mesothelioma
The Thoracic and Cardiovascular Surgeon 2023 February 3 [Link] İlteriş Türk, Gokturk Findik, Mehmet Çetin, Pinar Bicakcioglu, Selim Şakir Erkmen Gülhan, Koray Aydoğdu, Ülkü Yılmaz, Funda Demirağ Abstract Background: Complexities in TNM staging in epithelioid malignant pleural mesothelioma (MPM) may lead to errors in treatment selection, leading to major surgical interventions in patients with low…
Read MoreMultimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach
Translational Lung Cancer Research 2022 November [Link] Laura V Klotz, Hans Hoffmann, Rajiv Shah, Florian Eichhorn, Christiane Gruenewald, Elena L Bulut, Raffaella Griffo, Thomas Muley, Petros Christopoulos, Philip Baum, Peter Huber, Seyer Safi, Marc Kriegsmann, Michael Thomas, Helge Bischoff, Hauke Winter, Martin E Eichhorn Abstract Background: The exact role and type of surgery for malignant…
Read MoreThe Effects of Preserving the Diaphragm on Early and Late Outcome of Lung-Sparing Radical Surgery for Malignant Pleural Mesothelioma
Journal of Clinical Medicine 2022 November 19 [Link] Michelle Lee, Luigi Ventura, Ralitsa Baranowski, Joanne Hargrave, David Waller Abstract Background: The accepted aim of radical surgery for malignant pleural mesothelioma (MPM) is the achievement of macroscopic complete resection (MCR) whilst reducing perioperative morbidity by preserving normal tissue. Whilst preservation of the lung by pleurectomy/decortication (PD)…
Read MoreMultifactorial Evaluation following Cytoreductive Surgery for Malignant Pleural Mesothelioma in Patients with High Symptom-Burden
Journal of Clinical Medicine 2022 October 29 [Link] Riccardo Tajè, Roberto Fiorito, Alexandro Patirelis, Valentina Marziali, Vincenzo Ambrogi Abstract Mesothelioma has a scant prognosis and a great impact on symptoms and the quality of life. Pleurectomy/decortication and extrapleural pneumonectomy are the two cytoreductive surgical strategies, with different invasiveness, but achieving similar oncological results. Hereafter, the…
Read More